MEDICAL DEVICE 510K SUBMISSION
Purpose: The 510(k) submission is intended to demonstrate that a medical device is substantially equivalent to a legally marketed device (known as a predicate device) that is not subject to premarket approval. Substantial equivalence means that the new device has the same intended use and technological characteristics as the predicate device, or has different characteristics but does not raise new questions of safety and effectiveness.
Eligibility: Most medical devices that do not require premarket approval (PMA) are eligible for the 510(k) pathway. This includes moderate-risk (Class II) devices and some low-risk (Class I) devices that are not exempt from the 510(k) requirements.
Submission Preparation: The 510(k) submission package includes various components, such as a cover letter, administrative information, device description, indications for use, labeling, performance data, biocompatibility testing, software documentation (if applicable), and any other relevant information.
Identification of Predicate Device: The submission must identify the predicate device(s) to which the new device is claiming substantial equivalence. The predicate device(s) must be legally marketed in the United States and have the same intended use as the new device.
Review Process: Once the 510(k) submission is received by the FDA, the agency conducts a review to determine whether the new device is substantially equivalent to the predicate device(s). The review may involve assessing the device’s design, materials, performance data, labeling, and any other relevant information provided in the submission.
Decision: The FDA will issue a decision on the 510(k) submission based on the review findings. If the agency determines that the device is substantially equivalent to the predicate device(s) and meets all regulatory requirements, it will issue a clearance letter, allowing the device to be marketed in the United States.
Post-Market Requirements: After receiving clearance, the manufacturer is responsible for complying with post-market requirements, such as adverse event reporting, quality system regulations, and any specific conditions imposed by the FDA clearance letter.